COMPASS PATHWAYS PLC Operating Lease Cost
COMPASS PATHWAYS PLC (CMPS) reported Operating Lease Cost of $2.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-24
- COMPASS PATHWAYS PLC operating lease, cost for the quarter ending 2024-03-31 was $638.00K, a 11.34% increase year-over-year.
- COMPASS PATHWAYS PLC operating lease, cost for the quarter ending 2023-12-31 was $626.00K, a 14.86% increase year-over-year.
- COMPASS PATHWAYS PLC operating lease, cost for the quarter ending 2023-09-30 was $569.00K, a 0.35% increase year-over-year.
- COMPASS PATHWAYS PLC operating lease, cost for the quarter ending 2023-06-30 was $563.00K, a 4.74% decline year-over-year.
- COMPASS PATHWAYS PLC operating lease, cost for fiscal 2025 was $2.41M, a 6.30% decline from fiscal 2024.
- COMPASS PATHWAYS PLC operating lease, cost for fiscal 2024 was $2.57M, a 10.25% increase from fiscal 2023.
- COMPASS PATHWAYS PLC operating lease, cost for fiscal 2023 was $2.33M, a 3.00% increase from fiscal 2022.
- COMPASS PATHWAYS PLC operating lease, cost for fiscal 2022 was $2.26M, a 22.72% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.41M 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $2.57M 10-K · filed 2026-03-24 | |||
| 2024-03-31 | $638.00K 10-Q · filed 2024-05-08 | $1.26M derived: sum of 2 quarters · filed 2025-02-27 | $1.83M derived: sum of 3 quarters · filed 2025-02-27 | $2.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $626.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.20M derived: sum of 2 quarters · filed 2025-02-27 | $1.76M derived: sum of 3 quarters · filed 2025-02-27 | $2.33M 10-K · filed 2025-02-27 |
| 2023-09-30 | $569.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.13M derived: sum of 2 quarters · filed 2023-11-02 | $1.71M 10-Q · filed 2023-11-02 | $2.25M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.14M 10-Q · filed 2023-08-03 | $1.68M derived: sum of 3 quarters · filed 2024-05-08 | $2.25M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | $573.00K 10-Q · filed 2024-05-08 | $1.12M derived: sum of 2 quarters · filed 2024-05-08 | $1.69M derived: sum of 3 quarters · filed 2024-05-08 | $2.28M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $545.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.11M derived: sum of 2 quarters · filed 2024-02-29 | $1.70M derived: sum of 3 quarters · filed 2024-02-29 | $2.26M 10-K · filed 2024-02-29 |
| 2022-09-30 | $567.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.16M derived: sum of 2 quarters · filed 2023-11-02 | $1.72M 10-Q · filed 2023-11-02 | $2.54M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $591.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.15M 10-Q · filed 2023-08-03 | $1.97M derived: sum of 3 quarters · filed 2024-02-29 | $2.45M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $560.00K 10-Q · filed 2023-05-11 | $1.38M derived: sum of 2 quarters · filed 2024-02-29 | $1.86M derived: sum of 3 quarters · filed 2024-02-29 | $2.13M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.30M derived: sum of 2 quarters · filed 2024-02-29 | $1.57M derived: sum of 3 quarters · filed 2024-02-29 | $1.84M 10-K · filed 2024-02-29 |
| 2021-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $754.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.02M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $541.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $269.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |